Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.
As part of a clinical trial, the girl received CAR-T cell therapy, a treatment that requires removing some of a patient’s immune cells and programming them to target and kill cancer cells before ...
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
According to Emily Littlejohn, DO ... In her talk, she described outcomes for three patients who underwent CAR T-cell therapy to help attendees understand what can be expected in terms of efficacy ...
CAR-T cell therapy involves extracting a patient’s T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.
Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy. It uses a patient’s own immune system to fight certain blood cancers. Normal T cells can “hook” onto cancer cells and kill them, but ...
During a live event, John L. Wagner, MD, moderated a discussion on when to refer patients for CAR T-cell therapy and what ...
Chimeric Antigen Receptor (CAR) T cell therapy genetically alters a patient ... was approached by Emily Whitehead’s parents looking for a miracle to save their daughter as other doctors ...
The researchers also pinpoint how this transfer is regulated, which may be used to improve the efficacy of CAR-T cell therapy. The study has been published in the journal Science Immunology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback